{"": [219, 1938, 0], "Introduction": [1939, 7130, 0], "Single cell sorting and culture": [7140, 8656, 0], "Antibody and viral protein expression and purification": [8657, 10309, 0], "Virus culture and microneutralization": [10310, 10998, 0], "ELISA": [10999, 12019, 0], "Binding inhibition assay": [12020, 12753, 0], "Antibody Dependent Cellular Cytotoxicity (ADCC) assay": [12754, 13599, 0], "Antibody Dependent Enhancement (ADE) assay": [13600, 14360, 0], "Efficacy testing for SARS-CoV-2 infection in K18-ACE2 mice": [14361, 16189, 0], "Determination of lung viral load in infected mice": [16190, 17149, 0], "Cytokine and chemokine mRNA measurements": [17150, 18052, 0], "Methods": [7131, 18052, 1], "Efficacy testing in Golden Syrian hamsters": [18973, 22635, 0], "Efficacy testing in Indian rhesus macaques": [22636, 27301, 0], "Viral load determination in samples collected during hamster and macaque studies": [27302, 29346, 0], "Cytokine and chemokine protein measurements": [18053, 29346, 1], "SC31, a potent neutralizing antibody isolated from a convalescent patient, binds to a conserved region of RBD of the SARS-CoV-2 SP": [29356, 33096, 0], "SC31 requires Fc-mediated effector functions for maximal therapeutic efficacy against SARS-CoV-2 infection and does not cause ADE in K18-hACE2 mice": [33097, 38354, 0], "SC31 provides potent dose- and time-dependent therapeutic efficacy against SARS-CoV-2 infection in K18-hACE2 mice": [38355, 41105, 0], "SC31 provides potent therapeutic benefit, protecting against severe COVID-19-like disease in Golden Syrian hamsters infected with SARS-CoV-2": [41106, 44198, 0], "SC31 provides therapeutic benefit and eliminates infectious virus in a rhesus macaque model of COVID-19": [44199, 46642, 0], "Results": [29347, 46642, 1], "Discussion": [46643, 52464, 0], "Supporting information": [52465, 55262, 0]}